Registered API Intermediates & Raw Materials

Using in-house biocatalysis technology, Seqens has developed direct synthesis of D-Serine, as well as the full range of products in the ketamine family: Hydrochloride and free base, racemic and both chiral pure products, S-Ketamine and R-Ketamine.

Our portfolio of APIs and registered intermediaries synthesized in house include:

• D-Serine: To increase neuroplasticity and treat schizophrenia (under clinical evaluation)
• Esmolol HCl: FDA/EMA-approved in 1988 to treat atrial fibrillation
• Glycopyrrolate Tosylate: An anticholinergic to treat hyperhidrosis (under Clinical evaluation)
• Mefenamic Acid: A generic analgesic
• Methoxsalen: A generic antifungal that prevents or treats psoriasis
• Metolazone: A generic diuretic
• Norketamine: To treat chronic pain (under development)
• R-Ketamine HCl: To treat depression, and for pain management (under development)
• R-Praziquantel: An anthelmintic to treat parasitic worms (under clinical evaluation)
• S-Ketamine Base: To treat depression, and for pain management (under development)
• Safinamide: FDA/EMA-approved in 2017 and 2015, respectively, as an add-on treatment for Parkinson’s disease
• Sodium Benzoate: To treat urea cycle disorders associated with schizophrenia-like symptoms (under clinical evaluation)
• Toremifene citrate: Antineoplastic chemotherapy FDA/EMA-approved in 1997
  Ursodiol FDA/EMA-approved in 1987 and 1980, respectively, to treat primary biliary cirrhosis